nVision earns $12M in Series B for microcatheter development

Researchers writing on clipboards

Clinical-stage medical device company nVision Medical has earned $12 million in a Series B round. The funding will go toward product development, clinical studies and regulatory submission for the company’s microcatheter tech.

The microcatheter tech allows for doctors to access the fallopian tubes in the office without the need of any incisions or general anesthesia. The tech is currently focused in two areas: cell collection from the fallopian tubes and direct visualization of fallopian tube lumen.

The financing round was led by Arboretum Ventures, a new investor out of Ann Arbor, Michigan. Along with that, Tom Shehab will join the board of directors. All Series A investors took part in the Series B round as well.

Event

Join the world's top medtech executives virtually for the leading event in medtech — The Virtual MedTech Conference by AdvaMed

Expect the same high-quality education, world-class speakers and valuable business development in a virtual format. Experience more of the conference with on demand content and partnering, as well as livestreamed sessions.

"nVision's Series B financing validates the strength of our team's accomplishments to date,” said Surbhi Sarna, CEO and president of nVision, in a statement. “With the Series B financing, we are poised to further develop these technologies, seek additional regulatory clearances, and demonstrate clinical utility."

nVision has already earned FDA clearance earlier this year for a device that collects fallopian tube cells. The company also did a first-in-human case for a device that offers direct visualization of the fallopian tube.

"We believe nVision is tackling substantial unmet needs within women's health utilizing a very novel and very promising approach,” Shehab said in a statement. “With this new funding, the company is now well positioned to reach meaningful milestones in the year ahead."

- here's the press release

Related Articles:
Surefire Medical raises $11M to back its microcatheter oncology infusion system
FDA gives nod to Covidien's detachable tip microcatheter device

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.